ClinicalTrials.gg
RecruitingNCT06754358Updated Dec 31, 2024

Clinical Application Comparison of Two Femtosecond Laser Systems

A Phase 1 interventional study of LenSx and Z8 in Cataract, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University — 6 open to participants now, 6 under way, none of them phase 3. Cataract · Second Affiliated Hospital, School of Medicine, Zhejiang University.

Started
2024
with 3 others
Phase 1
Only one
of the 11
Registered
10th of 11
by date

Among the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, this one is one of 4 that started in 2024, is the only one in phase 1, and was the 10th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

6 of the 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Cataract by Second Affiliated Hospital, School of Medicine, Zhejiang University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the perioperative parameters of femtosecond laser-assisted cataract surgery (FLACS) using two laser systems.

Participants will:

Undergo FLACS using LenSx or Z8 femtosecond laser system Visit the clinic before the operation and 1 day, 1 week, and 1 month after the operation for checkups and tests Complete clinical measurements and dry eye questionnaires

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese Han patients aged 40 years or older
  2. clinical diagnosis of age-related cataracts;
  3. underwent FLACS with insertion of a posterior chamber IOL for the first eye.

Exclusion criteria

Exclusion Criteria:

  1. coexisting macular pathologies such as epiretinal membrane, macular hole or edema, or age-related macular degeneration. Patients with OCT scans of poor quality were excluded;
  2. preoperative flare of more than 15ph/ms11, ECD\<2000cells/mm2 or any other corneal pathologies;
  3. coexisting serious ocular diseases including uveitis, uncontrolled glaucoma, optic atrophy , amblyopia, retinopathies, or inflammatory pathology of the eye;
  4. history of intraocular trauma, surgery, or retinal laser procedures;
  5. usage of systemic or topical or NSAIDs within one month prior to surgery;
  6. patients with diabetes or any other systemic diseases that might confound the results or increase the risk for postoperative inflammation;
  7. intraoperative complications such as capsule tear, hyphema, vitreous loss, iris manipulation, or miosis after laser pre treatment requiring intracameral injection of epinephrine;
  8. ocular conditions contraindicating FLACS including poorly dilated pupils (\<5.0mm), narrow palpebral fissure, small hyperopic eyes with steep cornea (difficult to achieve suction), severe conjunctival chalasis, nystagmus, or lack of cooperation;
  9. potentially pregnant women;
  10. known sensitivity to concomitant medications used during perioperative period, participation in other clinical trial during the time of visit, or poor cooperation in diagnostic tests or non-compliance at follow-up.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    LenSx group

    Procedure: LenSx

  • Experimental
    Z8 group

    Procedure: Z8

Interventions

  • ProcedureLenSx

    Participants undergo FLACS using LenSx femtosecond laser system

  • ProcedureZ8

    Participants undergo FLACS using Z8 femtosecond laser system

06

What researchers measure

Primary outcomes

  1. ocular staining score

    The ocular staining score ranged from 0 to 12. A score of 0 indicated no corneal or conjunctival staining with fluorescein or lissamine green dye, respectively. A score of 12 indicated severe staining of the cornea and conjunctiva with confluent and central fluorescein staining, the presence of corneal filaments, and confluent areas of lissamine green of the bulbar conjunctiva of greater than or equal to 4 mm2.

    Time frame: 1 month after operation

Secondary outcomes

  1. ocular staining score

    The ocular staining score ranged from 0 to 12. A score of 0 indicated no corneal or conjunctival staining with fluorescein or lissamine green dye, respectively. A score of 12 indicated severe staining of the cornea and conjunctiva with confluent and central fluorescein staining, the presence of corneal filaments, and confluent areas of lissamine green of the bulbar conjunctiva of greater than or equal to 4 mm2.

    Time frame: 1 day and 1 week after operation

  2. phacoemulsification time

    Time frame: in the operation

  3. ultrasound power

    Time frame: in the operation

  4. vacuum docking time

    Time frame: in the operation

  5. femtosecond laser emission time

    Time frame: in the operation

  6. femtosecond laser-assisted capsulorhexis time

    Time frame: in the operation

  7. femtosecond laser-assisted pre-chop time

    Time frame: in the operation

  8. surgical time

    Time frame: in the operation

  9. surgical complication

    Time frame: in the operation

  10. DEQ-5 questionnaire

    The dry-eye questionnaire-5 (DEQ-5) is a validated questionnaire that has been shown to discriminate between different severities of dry eye. Participants self-assessed the frequency and severity of eye discomfort, eye dryness, and watery eyes experienced during the evening of a typical day within the last month. Responses were given using a Likert scale with scoring criteria from 0 = never experienced the symptom to 5 = extremely severe experience of symptom. The sum of the scores from the five questions was used in the analysis.

    Time frame: 1 week and 1 month after the operation

  11. OSDI questionnaire

    Ocular surface disease index (OSDI) is a widely accepted questionnaire on subjective symptoms in patients with dry eyes. It consisted of 12 questions on eye-related symptoms, vision-related function, and environment-related symptoms. Each question is evaluated according to the frequency of occurrence: never, 0 point; occasionally, 1 point; often, 2 points; most of the time, 3 points; all the time, 4 points. Not all the 12 questions needed to be answered. If the question is that the patient didn't participate in the activity or the environment that would not be in the case, it would not be answered and scored. The final score is calculated according to the formula: OSDI values=(sum of all survey items)×100/(answered survey items)×4.

    Time frame: 1 week and 1 month after the operation

  12. tear meniscus height

    The tear meniscus assessment height was measured with the Ocular Surface Analyser (SBM Sistemi, Orbassano, Italy)

    Time frame: 1 day, 1 week, and 1 month after the operation

  13. noninvasive tear film breakup time

    Noninvasive tear film breakup time was assessed automatically using the Ocular Surface Analyser (SBM Sistemi, Orbassano, Italy). The participants were instructed to blink naturally two times and then to cease blinking until instructed to blink again. Three measurements were performed for each eye and the average for each eye included for analysis.

    Time frame: 1 day, 1 week, and 1 month after the operation

  14. tear-film assessment

    The tear-film assessment was assessed with the Ocular Surface Analyser (SBM Sistemi, Orbassano, Italy).

    Time frame: 1 day, 1 week, and 1 month after the operation

  15. Schirmer I test

    The Schirmer I test was carried out under natural light. A 5 mm×35 mm Schirmer test strip was placed in the middle and outer 1/3 junction of the lower conjunctival sac of the affected eye without anesthesia. The patient was asked to close eyes gently. After 5min, the strip was removed and the wet length of the strip was measured. Values less than 5 mm are indicators for dry eye syndrome.

    Time frame: 1 day, 1 week, and 1 month after the operation

  16. visual acuity

    Time frame: 1 day, 1 week, and 1 month after the operation

  17. intraocular pressure

    Time frame: 1 day, 1 week, and 1 month after the operation

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2024 (actual). Primary completion is estimated for Aug 2025, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2024
First posted
Dec 31, 2024
StartActual
Oct 29, 2024
Primary completionEst.
Aug 31, 2025
CompletionEst.
Oct 31, 2025
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06754358
Responsible party
Sponsor
First posted
Dec 31, 2024
Start date
Oct 29, 2024
Primary completion
Aug 31, 2025 (estimated)
Completion
Oct 31, 2025 (estimated)
Last update
Dec 31, 2024

Study contacts

Kai Wang
Contact
wmzcmxxy@zju.edu.cn
+86 57187783897

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion